Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Jung, Klaus; Lein, Michael

doi:10.1016/j.bbcan.2014.09.001

Cited by 47 publications

(60 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many of the factors and signaling pathways involved in the progression and development of bone metastasis may be useful as biomarkers for early detection and monitoring the metastatic disease [40,49]. Deregulated bone metabolism is associated with the release of biochemical markers amenable to noninvasive measurement in blood or urine.…”

Section: Metastasis To Bonementioning

confidence: 99%

Metastatic Tumors to the Jaws and Mouth

Hirshberg

Berger

Allon

et al. 2014

Head and Neck Pathol

155

171

View full text Add to dashboard Cite

Metastatic dissemination to the oral cavity is rare and is usually the evidence of a wide spread disease with an average survival rate of 7 months. In almost a quarter of the cases, oral metastasis was found to be the first indication of an occult malignancy at a distant site. Metastatic lesions can be found anywhere in the oral cavity, however, the jawbones with the molar area is the most frequently involved site. In the oral soft tissues, the gingiva is the most common site, suggesting the possible role of inflammation in the attraction of metastatic deposits. The most common primary malignancies presenting oral metastases were the lung, kidney, liver, and prostate for men, and breast, female genital organs, kidney, and colorectum for women. Most patients with jawbone metastasis complain of swelling, pain, and paresthesia. An exophytic lesion is the most common clinical presentation of metastatic lesions in the oral soft tissues. Early lesions, mainly those located in the gingiva, may resemble a hyperplastic or reactive lesion. Once a lesion is recognized as metastasis, the primary tumor site should be identified following clinical, radiological and histopathological investigations. If standardized diagnostic workup fails to detect the site of origin, then the term carcinoma of unknown primary is applied. Personalized medicine tools such as tissue-oforigin assays should be applied, either by immunohistochemical testing or by molecular-profiling methods as these may lead to a more favorable outcome.

show abstract

Section: Metastasis To Bonementioning

confidence: 99%

Metastatic Tumors to the Jaws and Mouth

Hirshberg

Berger

Allon

et al. 2014

Head and Neck Pathol

155

171

View full text Add to dashboard Cite

show abstract

“…Its release into circulation corresponds predominantly to the matrix maturation phase of bone formation, an intermediate phase of osteoblast activity. 9 OC is a 5.8-kDa noncollagenous protein synthetized by osteoblasts that binds to hydroxyapatite and is involved in calcium binding. Glutamic acid residues in OC are converted to g-carboxyglutamic acid by vitamin K posttranslational carboxylation, and they are responsible for the calcium binding.…”

Section: Biochemical Markers Of Bone Turnovermentioning

confidence: 99%

“…8,9 Bone formation markers include osteoblastic enzymes or by-products of active osteoblasts during osteoblastogenesis. The majority of bone resorption markers are by-products of type I collagen degradation, noncollagenous bone matrix proteins or osteoclastic enzymes.…”

Section: Biochemical Markers Of Bone Turnovermentioning

confidence: 99%

Bone remodeling markers and bone metastases: From cancer research to clinical implications

Ferreira¹,

Alho²,

Casimiro³

et al. 2015

BoneKEy Reports

View full text Add to dashboard Cite

Bone metastasis is a frequent finding in the natural history of several types of cancers. However, its anticipated risk, diagnosis and response to therapy are still challenging to assess in clinical practice. Markers of bone metabolism are biochemical by-products that provide insight into the tumor-bone interaction, with potential to enhance the clinical management of patients with bone metastases. In fact, these markers had a cornerstone role in the development of bone-targeted agents; however, its translation to routine practice is still unclear, as reflected by current international guidelines. In this review, we aimed to capture several of the research and clinical translational challenges regarding the use of bone metabolism markers that we consider relevant for future research in bone metastasis.

show abstract

“…Интерес к биохимическим маркерам костного ре-моделирования как неинвазивным методам обследо-вания онкологических больных усиливается по мере внедрения в клиническую практику современных лабораторных технологий. Работы последних лет сви-детельствуют о возможности их применения не толь-ко в целях мониторинга и прогноза, но и для прове-дения ранней диагностики метастазов в костях [65]. …”

Section: заключениеunclassified

Biochemical markers of bone metastasis

Любимова¹,

Кушлинский²

2015

Usp. mol. onkol

View full text Add to dashboard Cite

Bone metastasis is one of the most frequent and dangerous complications of malignant tumors. The last years , achievements in the study of bone remodeling mechanisms promoted the search of sensitive and specific criteria reflecting the intensity of osteolysis and osteosynthesis in bone metastatic lesions. The most informative and clinically valid biochemical markers of bone formation and resorption are characterized in this review. The data on their possible implications in diagnostics, monitoring and prognosis of skeletal lesions by various malignant tumors are presented. The attention to biochemical markers of bone remodeling as noninvasive methods for oncologic patients examination is gradually increasing with adoption of modern laboratory technologies to clinical practice. The last years , publications suggest the possibility of their use both for monitoring, prognosis and early diagnostics of bone metastasis. We present the results of our own investigation of serum C-telopeptide of type I collagen (СТX) as bone resorption marker and bone-specific alkaline phosphatase (BAP) as formation marker in238 breast cancer patients using ELISA methods. The elevation of studied biochemical parameters in breast cancer patients was significantly associated with the extent of skeletal metastases (р < 0.02-0.00001), pathological fractures (р < 0.005-0.0001) and the severity of pain (р < 0.01-0.00002 Введение Метастазирование в кости -частое и опасное осложнение злокачественных опухолей, которое сни-жает продолжительность и качество жизни пациентов, вызывая сильные боли, патологические переломы, гиперкальциемию и компрессию спинного мозга. Наи-более часто в кости метастазирует рак простаты (54-85 %), рак молочной железы (РМЖ; 47-85 %), рак

show abstract

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Cited by 47 publications

References 168 publications

Metastatic Tumors to the Jaws and Mouth

Metastatic Tumors to the Jaws and Mouth

Bone remodeling markers and bone metastases: From cancer research to clinical implications

Biochemical markers of bone metastasis

Contact Info

Product

Resources

About